Physician profile
Devraj Lahiri
NPI 1356393458
$7,221.64
in general payments reported to CMS, 2019-2025
38 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,276 · 2020: $625 · 2021: $542 · 2022: $1,117 · 2023: $944 · 2024: $1,493 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,661.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,365.37 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $999.02 | 2019-2025 | Lokelma, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $768.06 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $318.35 | 2019-2025 | |
| Amgen INC. | $298.94 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $271.33 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Mylan Specialty L.P. | $255.29 | 2019-2024 | Yupelri |
| Pfizer INC. | $250.88 | 2019-2025 | |
| Amarin Pharma, INC. | $145.41 | 2020-2023 | |
| Abbott Laboratories | $143.06 | 2020-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.63 | 2019-2025 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $118.24 | 2024-2025 | |
| Medtronic, INC. | $107.12 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Currax Pharmaceuticals LLC | $95.80 | 2020-2025 | Contrave, Onzetra Xsail |
| United Therapeutics Corporation | $87.18 | 2022-2023 | Tyvaso |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $86.32 | 2019 | |
| Sunovion Pharmaceuticals INC. | $85.29 | 2019-2020 | |
| Philips North America LLC | $79.97 | 2019-2022 | |
| Genzyme Corporation | $68.95 | 2020-2024 | |
| Mallinckrodt Hospital Products INC. | $63.54 | 2025 | Acthar |
| Sanofi-Aventis U.S. LLC | $51.83 | 2019-2020 | |
| Exact Sciences Corporation | $50.38 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $47.36 | 2024-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $44.68 | 2023-2024 | Quviviq |
| Neurocrine Biosciences, INC. | $39.62 | 2024-2025 | Ingrezza |
| Grifols USA, LLC | $34.22 | 2020-2025 | Prolastin-C Liquid |
| Xeris Pharmaceuticals, INC. | $31.66 | 2024 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $28.57 | 2023-2024 | Eliquis |
| Allergan, INC. | $24.50 | 2020 | |
| Merck Sharp & Dohme LLC | $22.98 | 2019 | |
| Vivus LLC | $22.21 | 2020 | |
| Genentech USA, INC. | $18.77 | 2024 | Xolair |
| Viatris Specialty LLC | $18.32 | 2025 | Yupelri |
| Abbvie INC. | $14.97 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $14.87 | 2019 | |
| Eisai INC. | $14.21 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.74 | 2024 | Austedo Xr |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,866,043.80 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devraj Lahiri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.